Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis

BackgroundEvidence regarding the mortality benefit of implantable cardioverter defibrillator (ICD) non-ischemic dilated cardiomyopathy (NIDCM) is inconsistent. The most recent randomized study, the DANISH trial, did not find improved outcomes with ICD. However, based on previous studies and meta-ana...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Yotam Kolben, Bruria Hirsh Raccah, Ivelin Koev, David Luria, Offer Amir, Yitschak Biton
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2023-05-01
Rangatū:	Frontiers in Cardiovascular Medicine
Ngā marau:	ICD (implantable cardioverter-defibrillator) NIDCM SGLT 2 inhibitors ARNI angiotensin receptor neprilysin inhibitor sudden cardiac death (SCD)
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1192101/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!